Abstract
Multidrug resistance (MDR), characterized by a cross-resistance to many natural toxin-related compounds, may be caused either by overexpression of a drug efflux pump such as P-glycoprotein, (P-gP), multidrug resistance proteins MRP1-3, or BCRP/MXR or, in the case of DNA topoisomerase II active drugs, by a decrease in the enzymatic activity of the target molecule termed altered topoisomerase MDR (at-MDR). However, human small cell lung carcinoma (SCLC) cell lines showed a collateral sensitivity to 2',2'-difluorodeoxycytidine (gemcitabine, dFdC) and 1-beta-D-arabinofuranosylcytosine (ara-C). H69/DAU, a daunorubicin (DAU)-resistant variant of H69 with a P-gP overexpression, and NYH/VM, a VM-26 (teniposide)-resistant variant of NYH with an at-MDR, were both 2-fold more sensitive to gemcitabine and 7- and 2-fold more sensitive to ara-C, respectively. MDR variants had a 4.3- and 2.0-fold increased activity of deoxycytidine kinase (dCK), respectively. dCK catalyzes the first rate-limiting activation step of both gemcitabine and ara-C. In addition, deoxycytidine deaminase, responsible for inactivation of dFdC and ara-C, was 9.0-fold lower in H69/DAU cells. The level of thymidine kinase 2, a mitochondrial enzyme that can also phosphoryl...Continue Reading
References
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·P B JensenH H Hansen
Apr 30, 1991·Biochemical and Biophysical Research Communications·S ErikssonN G Johansson
Jun 1, 1991·Journal of Medicinal Chemistry·C H BakerR Resvick
Jan 10, 1989·Biochemistry·N S DattaI H Fox
Aug 1, 1989·Analytical Biochemistry·P A Sherman, J A Fyfe
Dec 1, 1989·British Journal of Cancer·P B JensenH H Hansen
Jun 1, 1985·Cancer Research·D N CarneyJ D Minna
Aug 23, 1983·Biochimica Et Biophysica Acta·G J PetersJ H Veerkamp
Sep 1, 1981·Canadian Journal of Biochemistry·D Hunting, J F Henderson
Nov 23, 1995·The New England Journal of Medicine·H M Pinedo, G Giaccone
Sep 15, 1995·The Journal of Biological Chemistry·T W Loo, D M Clarke
Jul 1, 1995·Leukemia Research·S E NielsenJ Mejer
Oct 7, 1994·Biochemical Pharmacology·V W Ruiz van HaperenG J Peters
May 1, 1993·The Journal of Clinical Investigation·W N HaitJ R Murren
Mar 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y CormierD Wong
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V W Ruiz van HaperenG J Peters
Aug 17, 1993·Biochemical Pharmacology·V W Ruiz van HaperenG J Peters
Feb 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P E KristjansenH H Hansen
May 25, 1993·Biochemical Pharmacology·P B JensenH H Hansen
Jan 17, 1996·International Journal of Cancer. Journal International Du Cancer·M A IzquierdoR J Scheper
Feb 1, 1996·Leukemia Research·P NoordhuisG J Peters
Apr 12, 1996·Biochemical Pharmacology·V W van HaperenG Peters
Dec 1, 1995·Anti-cancer Drugs·W PlunkettV Gandhi
Jan 1, 1997·British Journal of Cancer·P B JensenM Sehested
Jun 17, 1997·Biochemistry·T L HughesD S Shewach
Aug 1, 1997·American Journal of Clinical Oncology·N SavarajL G Feun
Nov 5, 1998·Biochemical Pharmacology·M Sasvári-SzékelyM Staub
Feb 5, 1999·Biochemical Pharmacology·A M BergmanG J Peters
Feb 5, 1999·Biochemical Pharmacology·C J van MoorselG J Peters
Feb 16, 1999·FEBS Letters·L WangS Eriksson
May 20, 1999·Surgery Today·D AlexanderS Kasai
Mar 4, 2000·Biochimica Et Biophysica Acta·C J van MoorselG J Peters
Citations
Jul 20, 2002·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Andries M BergmanGodefridus J Peters
Sep 2, 2008·Cancer Research·Liang LiLiewei Wang
Sep 19, 2009·Trends in Pharmacological Sciences·Matthew D HallMichael M Gottesman
Apr 29, 2009·The Prostate·Peter JantscheffUlrich Massing
Jan 6, 2010·Critical Reviews in Oncology/hematology·David J Stewart
Sep 21, 2013·Investigational New Drugs·Godefridus J PetersDeog Joong Kim
Aug 8, 2009·Biochemical Pharmacology·Swathi DamarajuCarol E Cass
Aug 8, 2015·Nucleosides, Nucleotides & Nucleic Acids·Anna Fyrberg, Kourosh Lotfi
Nov 15, 2011·Expert Opinion on Drug Delivery·Christian CeliaMassimo Fresta
Oct 11, 2012·Life Sciences·Makrem Ben ReguigaLaurence Bonhomme-Faivre
Jul 16, 2008·Biochimica Et Biophysica Acta·László SeresLászló Homolya
Apr 14, 2015·BioMed Research International·Zhengzi QianHuaqing Wang
Apr 7, 2005·British Journal of Cancer·M NgD Catovsky
Jun 12, 2003·British Journal of Cancer·A M BergmanG J Peters
Jun 30, 2004·The Pharmacogenomics Journal·A K FukunagaH L McLeod
Mar 5, 2003·Pharmacological Reviews·Romano DanesiMario Del Tacca
Sep 10, 2003·Anti-cancer Drugs·Vicki L LockeMary W Davey
Nov 21, 2007·Molecular Cancer Therapeutics·Luni EmdadPaul B Fisher
Jun 6, 2003·Biochemical Pharmacology·Zsolt CsapoMaria Sasvari-Szekely